in HIV-Associated
Cryptococcal Meningitis
Caroline Ratnasari Sarwono Denia Anissa Kurniasari Ivana Jessica Cindy Graciela
(01073190113) (01073200131) (01073200124)
Published
February 11, 2016
Tatalaksana belum banyak berubah dalam 20 tahun, dan belum ada anticryptococcal agents
baru dalam waktu dekat
Cryptococcal antigen
Flow Lateral Assay (+)
EXCLUSION CRITERIA
RANDOMIZATION LABORATORY
TREATMENT
Dexamethasone atau plasebo yang identik
STATISTICAL ANALYSIS
Primary outcome
Cox proportional hazards & Kaplan-Meier plots
Secondary outcome
Logistic regression, Longitudinal Log-CSF quantitative,
Fisher’s exact test
Jumlah Sampel
823 partisipan
Pengelompokkan
Dexamethasone 224
Placebo 227
BASELINE CHARACTERISTIC
OUTCOMES
SURVIVAL AMONG ALL PATIENTS
ACCORDING TO CONTINENT
Adverse Events
6 Months
P value = 0.01
Total number grade 3 or 4: P value = 0.02
1023 dexamethasone
835 placebo
DISCUSSION
Dexamethasone
Hipotesis :
- Tekanan cairan otak dan intrakranial
- Komplikasi inflamasi
- Insiden kejadian IRIS
(Immune Reconstitution Inflammatory
Syndrome)
Quantitative Fungal Counts
Cerebrospinal Fluid (CSF)
Hipotesis
Dexamethasone
C Placebo
YES
YES
YES
YES
227 assigned to receive placebo → 226 were included in the intention-to-treat analysis
Were measures objective or were the patients and
clinicians kept “blind” to which treatment was being
received?
YES
NO
YES
NO
Dexamethasone did not reduce mortality among patients with HIV-associated cryptococcal
meningitis and was associated with more adverse events and disability than placebo
THANK
YOU